NDANASALSPRAY, METERED
Approved
Feb 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNAREL (nafarelin acetate) is a gonadotropin-releasing hormone (GnRH) agonist administered as a nasal spray for the treatment of endometriosis and precocious puberty. It works by initially stimulating then suppressing the release of luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. The metered nasal spray formulation allows for convenient outpatient dosing.
$0.204MPart D
LOE ApproachingLate-stage product with minimal Part D claims (58 in 2023) indicates a mature, contracted market with limited team expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYNAREL generated zero linked job postings, indicating minimal active hiring or team growth. Working on this product typically involves defending market share against generics and optimizing profitability in a contracted, mature indication space.
Company
Worked on SYNAREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.